These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 26772905

  • 21. Unacceptable side-effects associated with a hyperosmolar vaginal microbicide in a phase 1 trial.
    Lacey CJ, Woodhall S, Qi Z, Sawant S, Cowen M, McCormack S, Jiang S.
    Int J STD AIDS; 2010 Oct; 21(10):714-7. PubMed ID: 21139151
    [Abstract] [Full Text] [Related]

  • 22. Pharmacokinetics of the Protein Microbicide 5P12-RANTES in Sheep following Single-Dose Vaginal Gel Administration.
    McBride JW, Dias N, Cameron D, Offord RE, Hartley O, Boyd P, Kett VL, Malcolm RK.
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784672
    [Abstract] [Full Text] [Related]

  • 23. Safety and acceptability of 6% cellulose sulfate vaginal gel applied four times per day for 14 days.
    Doh AS, Ngoh N, Roddy R, Lai JJ, Linton K, Mauck C.
    Contraception; 2007 Sep; 76(3):245-9. PubMed ID: 17707724
    [Abstract] [Full Text] [Related]

  • 24. Biocompatibility of solid-dosage forms of anti-human immunodeficiency virus type 1 microbicides with the human cervicovaginal mucosa modeled ex vivo.
    Trifonova RT, Pasicznyk JM, Fichorova RN.
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4005-10. PubMed ID: 17030562
    [Abstract] [Full Text] [Related]

  • 25. Dilution of microbicide gels with vaginal fluid and semen simulants: effect on rheological properties and coating flow.
    Lai BE, Xie YQ, Lavine ML, Szeri AJ, Owen DH, Katz DF.
    J Pharm Sci; 2008 Feb; 97(2):1030-8. PubMed ID: 17724667
    [Abstract] [Full Text] [Related]

  • 26. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004).
    McGowan I, Gomez K, Bruder K, Febo I, Chen BA, Richardson BA, Husnik M, Livant E, Price C, Jacobson C, MTN-004 Protocol Team.
    AIDS; 2011 May 15; 25(8):1057-64. PubMed ID: 21505316
    [Abstract] [Full Text] [Related]

  • 27. Semi-solid gels function as physical barriers to human immunodeficiency virus transport in vitro.
    Lai BE, Geonnotti AR, Desoto MG, Montefiori DC, Katz DF.
    Antiviral Res; 2010 Nov 15; 88(2):143-51. PubMed ID: 20709109
    [Abstract] [Full Text] [Related]

  • 28. Mucosal integrity and inflammatory markers in the female lower genital tract as potential screening tools for vaginal microbicides.
    Su HI, Schreiber CA, Fay C, Parry S, Elovitz MA, Zhang J, Shaunik A, Barnhart K.
    Contraception; 2011 Nov 15; 84(5):525-32. PubMed ID: 22018129
    [Abstract] [Full Text] [Related]

  • 29. Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels: effects on markers of inflammation and innate immunity in cervicovaginal fluid.
    Anderson DJ, Williams DL, Ballagh SA, Barnhart K, Creinin MD, Newman DR, Bowman FP, Politch JA, Duerr AC, Jamieson DJ.
    Am J Reprod Immunol; 2009 Feb 15; 61(2):121-9. PubMed ID: 19143675
    [Abstract] [Full Text] [Related]

  • 30. Does tenofovir gel or do other microbicide products affect detection of biomarkers of semen exposure in vitro?
    Snead MC, Kourtis AP, Melendez JH, Black CM, Mauck CK, Penman-Aguilar A, Chaney DM, Gallo MF, Jamieson DJ, Macaluso M, Doncel GF.
    Contraception; 2014 Aug 15; 90(2):136-41. PubMed ID: 24746557
    [Abstract] [Full Text] [Related]

  • 31. Pharmacokinetic modeling of a gel-delivered dapivirine microbicide in humans.
    Halwes ME, Steinbach-Rankins JM, Frieboes HB.
    Eur J Pharm Sci; 2016 Oct 10; 93():410-8. PubMed ID: 27559026
    [Abstract] [Full Text] [Related]

  • 32. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women.
    El-Sadr WM, Mayer KH, Maslankowski L, Hoesley C, Justman J, Gai F, Mauck C, Absalon J, Morrow K, Mâsse B, Soto-Torres L, Kwiecien A.
    AIDS; 2006 May 12; 20(8):1109-16. PubMed ID: 16691061
    [Abstract] [Full Text] [Related]

  • 33. Quantitative imaging and sigmoidoscopy to assess distribution of rectal microbicide surrogates.
    Hendrix CW, Fuchs EJ, Macura KJ, Lee LA, Parsons TL, Bakshi RP, Khan WA, Guidos A, Leal JP, Wahl R.
    Clin Pharmacol Ther; 2008 Jan 12; 83(1):97-105. PubMed ID: 17507921
    [Abstract] [Full Text] [Related]

  • 34. Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1.
    Mahalingam A, Simmons AP, Ugaonkar SR, Watson KM, Dezzutti CS, Rohan LC, Buckheit RW, Kiser PF.
    Antimicrob Agents Chemother; 2011 Apr 12; 55(4):1650-60. PubMed ID: 21245437
    [Abstract] [Full Text] [Related]

  • 35. Colposcopy: still useful in microbicide safety trials?
    Mauck CK, Weiner DH, Lai JJ, Schwartz JL.
    Sex Transm Dis; 2012 Jun 12; 39(6):465-9. PubMed ID: 22592833
    [Abstract] [Full Text] [Related]

  • 36. Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides.
    Catalone BJ, Kish-Catalone TM, Budgeon LR, Neely EB, Ferguson M, Krebs FC, Howett MK, Labib M, Rando R, Wigdahl B.
    Antimicrob Agents Chemother; 2004 May 12; 48(5):1837-47. PubMed ID: 15105142
    [Abstract] [Full Text] [Related]

  • 37. Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm: a randomized controlled trial.
    Barnhart KT, Rosenberg MJ, MacKay HT, Blithe DL, Higgins J, Walsh T, Wan L, Thomas M, Creinin MD, Westhoff C, Schlaff W, Archer DF, Ayers C, Kaunitz A, Das S, Moench TR.
    Obstet Gynecol; 2007 Sep 12; 110(3):577-86. PubMed ID: 17766603
    [Abstract] [Full Text] [Related]

  • 38. Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides.
    Forbes CJ, McCoy CF, Murphy DJ, Woolfson AD, Moore JP, Evans A, Shattock RJ, Malcolm RK.
    J Pharm Sci; 2014 May 12; 103(5):1422-32. PubMed ID: 24585370
    [Abstract] [Full Text] [Related]

  • 39. Safety trial of the vaginal microbicide cellulose sulfate gel in HIV-positive men.
    Jespers V, Buvé A, Van Damme L.
    Sex Transm Dis; 2007 Jul 12; 34(7):519-22. PubMed ID: 17297382
    [Abstract] [Full Text] [Related]

  • 40. Phase I randomized safety study of twice daily dosing of acidform vaginal gel: candidate antimicrobial contraceptive.
    Keller MJ, Carpenter CA, Lo Y, Einstein MH, Liu C, Fredricks DN, Herold BC.
    PLoS One; 2012 Jul 12; 7(10):e46901. PubMed ID: 23056520
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.